MedTrace Logo

Diagnostic Value of Patient - Reported and Clinically Verified Olfactory Disorders (COVID-19)

NCT04407494 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 809

Last updated 2020-06-01

No results posted yet for this study

Summary

Participants are healthcare workers and adult outpatients referred in a COVID-19 screening center. Patients-reported symptoms are collected, then participants underwent a simple olfactory test (CODA for Clinical Olfactory Dysfunction Assessment), prior to swabbing for SARS-CoV-2 diagnosis (RT-PCR). We aimed to evaluate the prevalence of smell and taste disorders, and to calculate the diagnostic value of patient-reported and clinically verified smell disorders in persons with suspected COVID-19.

Conditions

Interventions

BIOLOGICAL

Reporting of anosmia, ageusia and other clinical symptoms

Reporting of anosmia, ageusia and other clinical symptoms related to COVID-19 - CODA test - SARS-CoV2 RT-PCR and ELISA

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Fréderic VENAIL, PU-PH · UH Montpellier

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2020-04-01
Completion
2020-04-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04407494 on ClinicalTrials.gov